Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Synta Pharmaceuticals Corp.
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• confirmed diagnosis of NSCLC

• Stage IIIB or IV NSCLC

• ECOG Performance Status 0 or 1

• Prior therapy defined as 1 prior systemic therapy for advanced disease

• measurable disease

• Radiologic evidence of disease progression following most recent prior treatment.

• Adequate hematologic, hepatic, renal function

Exclusion Criteria:

• Active or untreated CNS metastases

• Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin

• Serious cardiac illness or medical conditions

• Pregnant or lactating women

• Uncontrolled intercurrent illness